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Abstract 
Several acutely acting antimigraine drugs, including sumatriptan and other second generation 5-HT1D receptor agonists, have the 
ability to constrict porcine carotid arteriovenous anastomoses a  well as the human isolated coronary artery. These two experimental 
models eem to serve as indicators, respectively, for the therapeutic and coronary side-effect potential of the compounds. Using these two 
models, we have now investigated the effects of GMC2021 (3-[2-(dimethylanimo)ethyl]-5-[(trifluoromethyl)sulfonyl]oxy][1H]indole 
oxalate, a close analogue of sumatriptan. GMC2021 (30, 100, 300 and 1000 ~g • kg-1, i.v.) decreased the total carotid blood flow by 
exclusively decreasing arteriovenous anastomotic blood flow; capillary blood flow to the skin and ears was moderately increased. The 
mean + S.E.M. dose of GMC2021 eliciting a 50% decrease (EDso) in the porcine carotid arteriovenous anastomotic blood flow was 
found to be 1.1 + 0.3 I~mol. kg -I  and the highest dose (1000 I~g" kg -1) produced a 67_ 4% reduction. The carotid haemodynamic 
effects of GMC2021 were reduced by the selective 5-HT1D receptor antagonist, GR127935 (N-[methoxy-3-(4-methyl-1- 
piperaziny•)pheny•]-2'-methy•-4'-(5-methy•-••2•4-•xadiaz••-3-y•)[•••-bipheny•]-4-carb•xamide hydrochloride), which completely antago- 
nizes porcine carotid haemodynamic responses to sumatriptan (EDs0:0.16 ixmol.kg -~, i.v.). Compared to sumatriptan (pD2: 
6.12 + 0.15; Em~: 31.3 + 12.3% of contractions to 100 mM K+), GMC2021 was less potent in constricting the human isolated coronary 
artery (pD2:5.45 + 0.2; Emax: 21.0 + 4.8% of contractions to 100 mM K+). The above results suggest that GMC2021 constricts carotid 
arteriovenous anastomoses partly by a 5-HT1D receptor and partly by another, probably novel, receptor and that GMC2021 should be able 
to abort migraine headaches in patients, with perhaps a less propensity for coronary side effects. 
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1. Introduction 
Recent progress in the field of migraine has led to the 
introduction of sumatriptan, the first of a completely new 
class of compounds, designated as 5-HT~-like receptor 
agonists (for details, see Humphrey et al., 1990; Saxena 
and Ferrari, 1992). Sumatriptan, which effectively aborts 
migraine headaches (The Subcutaneous Sumatriptan I ter- 
national Study Group, 1991; Ferrari and Saxena, 1993), 
constricts large cranial and extracranial blood vessels (see 
* Corresponding author. Tel.: (+ 31)-(10)-408 7537/47; fax: (+ 31)- 
(10)-436 6839; email: Saxena@Farma.Fgg.Eur.NL 
Saxena and Tfelt-Hansen, 1993), including porcine carotid 
arteriovenous anastomoses (Den Boer et al., 1991a, 1992). 
The constriction of porcine arteriovenous anastomoses by 
sumatriptan is mediated via the 5-HTl-like receptor, be- 
cause this effect is antagonized by methiothepin, but not 
by ketanserin (Saxena et al., 1986; Hoyer et al., 1994). 
Evidence is now emerging that this vascular 5-HTl-like 
receptor may be identical to the recombinant 5-HTtD, most 
probably 5-HT1Dt3 , receptor. Thus, the mRNA for the 
5-HT~D ~, but not that for 5-HT1D~, receptor is present in 
cranial blood vessels (Hamel et al., 1993) and the vasocon- 
striction by sumatriptan, which has a high affinity for 
5-HT m receptors (Peroutka nd McCarthy, 1989; Beattie 
et al., 1994), is antagonized by GR127935, a selective 
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2. Materials and methods 
CF~'SO2 ~ O~__CH2.CH=.N(CH3)= 
I H 
CH3-NH-SO=I~~--CH='CH='N(CHs)= 
I H 
Fig. 1. Chemical structures of GMC2021 and sumatriptan. 
5-HTID receptor antagonist (Skingle et al., 1993; Clitherow 
et al., 1994; De Vries et al., 1996). 
The success of sumatriptan i antimigraine therapy has 
prompted the synthesis and evaluation of new compounds 
with binding affinity and potential agonist activity at 5- 
HTID receptors (for a review, see Saxena et al., 1996). 
One such compound, synthesized at the Department of 
Medicinal Chemistry, Faculty of Pharmacy, The State 
University, Groningen, Netherlands, is GMC2021, which 
is a close analogue of sumatriptan (Fig. 1). Like sumatrip- 
tan, GMC2021 shows selectivity for 5-HTID receptors; the 
pK i values of sumatfiptan (Beattie et al., 1994) and 
GMC2021 (K. Svensson, unpublished observations) on 
cells transfected with human receptor clones are, respec- 
tively: 5-HT1A, 7.00 and 7.40; 5-HT~D ~, 8.50 and 8.50 and 
5-HT~D ~, 8.10 and 7.50. Furthermore, at10 IxM GMC2021 
inhibited forskolin-stimulated cAMP formation by 94% 
and 84%, respectively, in cells with human 5-HTm~ and 
5-HTID ~ receptors (K. Svensson, unpublished observa- 
tions). In the present investigation, we have studied the 
effects of GMC2021 in experimental models predictive of 
therapeutic activity in migraine (constriction of carotid 
arteriovenous anastomoses in anaesthetized pigs; Saxena, 
1990, 1995) and coronary side effects (constriction of 
human isolated coronary artery; Connor et al., 1989; Bax 
et al., 1993). In the latter model, sumatriptan was simulta- 
neously used for a direct comparison, whereas data ob- 
tained in the first model were compared with that obtained 
with sumatriptan in a recent series of experiments (De 
Vries et al., 1996). 
2.1. Systemic and carotid haemodynamics n anaesthetized 
pigs 
2.1.1. General 
After an overnight fast, 12 domestic pigs (Yorkshire × 
Landrace; 10-15 kg) were anaesthetized with azaperone 
(160 mg, i.m.), midazolan hydrochloride (5 mg, i.m.) and 
metomidate (200 rag, i.v.), intubated and connected to a 
respirator (BEAR 2E, BeMeds AG, Baar, Switzerland) for 
intermittent positive pressure ventilation with a mixture of 
room air and oxygen. Respiratory rate, tidal volume and 
oxygen supply were adjusted to keep arterial blood gas 
values within physiological limits (pH: 7.35-7.48; pCO2: 
35-48 mm Hg; pOz: 100-120 mm Hg). Anaesthesia was 
maintained with a continuous i.v. infusion of pentobarbi- 
tone sodium at 20 mg. kg -1. h 1. With this anaesthetic 
regimen, arteriovenous anastomotic blood flow is consider- 
ably higher than that in pigs in a conscious tate or under 
thiopentone anaesthesia (Den Boer et al., 1993). 
Catheters were placed in the inferior vena cava via the 
left femoral vein for the administration of drugs and in the 
aortic arch via the left femoral artery for the measurement 
of arterial blood pressure (P23 Dc pressure transducer; 
Statham, Hato Rey, Puerto Rico) and the withdrawal of 
arterial blood for determining blood gases (ABL-510, Ra- 
diometer, Copenhagen, Denmark). The common carotid 
arteries, external jugular veins and vagus nerves were 
identified and both vagi and the accompanying cervical 
sympathetic nerves were cut between two ligatures. An- 
other catheter was placed in the right external jugular vein 
for the withdrawal of venous blood samples, while the 
right common carotid artery was dissected free and a 
needle was inserted against he direction of blood flow for 
the administration and uniform mixing of radioactive mi- 
crospheres. Blood flow was measured in the right common 
carotid artery with a flow probe (internal diameter: 2.5 
mm) connected to a sine-wave lectromagnetic flow meter 
(Transflow 601-system, Skalar, Delft, Netherlands). Heart 
rate was measured with a tachograph (7P4 Grass Instru- 
ment Company, Quincy, Mass, USA) triggered by electro- 
cardiogram signals. 
Arterial blood pressure, heart rate and carotid blood 
flow were continuously monitored on a model 7 Grass 
polygraph. During the experiment body temperature was 
kept at about 37°C and the animals were continuously 
infused with saline to compensate for fluid losses. 
2.1.2. Distribution of carotid blood flow 
The distribution of common carotid blood flow was 
determined with 15 + 1 (S.D.) Ixm diameter microspheres 
labelled with either 14lee, ll3Sn, 95Nb, I°3RH or 46Sc 
(NEN Company, Dreieich, Germany). For each measure- 
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ment a suspension of about 200 000 microspheres, labelled 
with one of the isotopes, was mixed and injected into the 
carotid artery. At the end of the experiment, he animal 
was killed and the heart, kidneys, lungs and the different 
cranial tissues were dissected out, weighed and put in 
vials. The radioactivity in these vials was counted for 5-10 
min in a "y-scintillation counter (Packard, Minaxi auto- 
gamma 5000), using suitable windows for discriminating 
the different isotopes. All data were processed by a set of 
specially designed programs (Saxena et al., 1980), using a 
personal computer. 
The fraction of carotid blood flow distributed to the 
different issues was calculated by multiplying the ratio of 
tissue and total radioactivities by the total common carotid 
blood flow at the time of the injection of microspheres. 
Since little or no radioactivity was detected in the heart 
and kidneys, all microspheres trapped in lungs reached this 
tissue from the venous side after escaping via carotid 
arteriovenous anastomoses. Therefore, the amount of ra- 
dioactivity in the lungs was used as an index of the 
arteriovenous anastomotic fraction of carotid blood flow 
(Johnston and Saxena, 1978; Saxena and Verdouw, 1982). 
2.1.3. Experimental protocol 
The experiments were started after a stabilization period 
of about 1 h. Thereafter, the animals were divided into two 
groups which received slow i.v. injections of either saline 
(5ml;  n=6)  o rGR127935(0 .5mg'kg  l; n=6)  overa 
period of 3-4 min. After another 15 rain, baseline values 
of heart rate, mean arterial blood pressure, carotid blood 
flow and its distribution as well as arterial and jugular 
venous blood gases were measured. Subsequently, both 
groups of animals received cumulative i.v. doses of 
GMC2021 (30, 100, 300 and 1000 I~g.kg -1) every 20 
min. Fifteen minutes after each dose of GMC2021, all 
haemodynamic variables were assessed again. 
2.2. Human isolated coronary artery 
As described previously (Bax et al., 1993), the right 
epicardial coronary artery was obtained (via the Rotterdam 
Heart Valve Bank, Bio Implant Services/Eurotransplant 
Foundation) from 5 'heart beating' organ donors (3 males 
and 2 females between the ages of 4 and 52 years with 
mean _+ S.E.M. 35 ___ 8 years), who died of cerebrovascular 
accident less than 24 h before the tissue was brought o the 
laboratory. Vessel segments containing macroscopically 
visible atherosclerotic lesions were excluded from the study 
and no attempt was made to denude endothelium. 
Coronary artery segments (approximately 4 mm each) 
were suspended on stainless steel hooks in 15 ml organ 
baths containing Krebs bicarbonate solution (composition 
in mM: NaCI 118, KC1 4.7, CaC12 2.5, MgSO 4 1.2, 
KH2PO 4 1.2, NaHCO 2 25 and glucose 8.3; pH 7.4), 
aerated with 95% O 2 and 5% CO 2 at 37°C. They were 
allowed to equilibrate for at least 30 min, with change of 
solution twice at a 15 min interval. Changes in tension 
were recorded with a Harvard isometric transducer. The 
vessel segments, stretched to a stable tension of about 15 
mN, were exposed to 30 mM K-- twice. Subsequently, the 
functional integrity of the endothelium was verified by 
observing relaxation to substance P (1 nM) after precon- 
traction with prostaglandin F2~ (1 tzM). After washout, the 
tissue was exposed to 100 mM K ÷ to determine the 
maximum contractile response to K +. After another 30 
min equilibration period, a concentration response curve to 
either GMC2021 or sumatriptan (n = 5 each) was con- 
structed. Contractile responses to GMC2021 and sumatrip- 
Table 1 
Absolute values of heart rate, mean arterial blood pressure and difference in arterial and jugular venous oxygen saturation at baseline and after cumulative 
doses of GMC2021 in animals pre-treated with either saline (n = 6) or GR127935 (0.5 mg - kg-I ;  n = 6) 
Pretreatment GMC2021 (i.zg • kg-l  ) ~:~ 
Baseline 30 100 300 1000 
Heart rate (beats. min- I) ~" 
Saline 94±2 93_+2( -  1 +0)  ~ 91 -+ 2 ( -3 -+ 0) a 905:2( -4+_1)  a ~, 89±2( -5±1)  a 
GR127935 96-+6 95 ±6( -1  -+ 1) 93±6( -3+_  1) a 92-+6( -5  + 1) a 90±5 ( -7± 1) a 
Mean arterial blood pressure (mm Hg) 
Saline 98+3 94+4( -5_+1)  a 88±4( -11+1)  ~ 
GR127935 102_+6 101 ±7( -1  ±2)  99_+8 ( -3_+4)  
Arteriot,enous difference in oxygen saturation (%) 
Saline 10.1 + 1.5 11.6 + 2.7 (9 + 10) 
GR127935 5.4 -+ 1.4 5.6 -+ 1.4 (7 + 6) 
11.2+ 1.9 (14_+ 12) 
5.2+ 1 .6 ( -8+ 10) 
79_+3(--20_+ 1) a 
96_+8 ( - -6±4)  b 
14.6_+2.1 (47_+8) 
5.2 + 1.6 (--4_+ 12) 
69+2( -30_+ l) a 
91 _+ 8 (--11_+ l) a'b 
18.9 + 2.9 (102 + 36) ~ 
6.5+1.8 (25+14) 
Percentage changes from baseline in each variable is given in parentheses. All values have been presented as means + S.E.M. ~ P < 0.05 vs. baseline; 
b p < 0.05 vs. corresponding dose in the saline-pre-treated group. 
tan were expressed as a percentage of the contraction 
induced by 100 mM K +. 
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Fig. 2. Effect of GMC2021 (30-1000 i~g.kg -a ) on the total carotid 
blood flow and its arteriovenous anastomotic (AVA) and nutrient 
(capillary) fractions in anaesthetized pigs, pre-treated with either saline 
(n = 6) or GR127935 (0.5 mg. kg-  n ; n = 6). All values are presented as 
means 5: S.E.M. * P < 0.05 vs. baseline. 
dam 'Dijkzigt', dealing with the use of animals and hu- 
mans in scientific experiments. 
2.4. Data presentation and statistical analysis 
All data have been expressed as means + S.E.M. The 
significance of the changes (from baseline values) induced 
by the different doses of GMC2021 was evaluated with 
Duncan's new multiple range test, once an analysis of 
variance (randomized block design) had revealed that the 
samples represented ifferent populations. The changes 
caused by GMC2021 in saline- and GR127935-pre-treated 
groups at corresponding doses were compared by using a 
Student's t-test. Statistical significance was accepted at 
P < 0.05 (two-tailed). In the saline-pre-treated group, the 
dose of GMC2021 eliciting a 50% decrease (EDs0) in 
arteriovenous anastomotic blood flow was calculated using 
linear regression analysis. 
2.5. Chemical compounds 
Apart from the anaesthetics, azaperone, metomidate 
(both from Janssen Pharmaceutica, Beerse, Belgium), mi- 
dazolan hydrochloride (Hoffmann La Roche, Mijdrecht, 
Netherlands) and pentobarbitone sodium (Apharmo, Am- 
hem, Netherlands), the compounds used in this study were: 
prostag land in  F2a ('Iris salt) and substance P acetate (both 
purchased from Sigma Chemical Co., St. Louis, MO, 
USA); GMC2021 (3-[2-(dimethylanimo)ethyl]-5-[(tdflu- 
oromethyl)sulfonyl]oxy][1H]indole oxa ate; Department of
Medicinal Chemistry, University of Groningen, Nether- 
lands), sumatriptan succinate, GR127935 (N-[methoxy-3- 
(4-methyl- 1-piperazinyl)phenyl]-2'-methyl-4'-(5-methyl- 1, 
2,4-oxadiazol-3-yl)[ l, 1-biphenyl]-4-carboxamide hydro- 
chloride (both gifted by Dr. Helen Connor, Glaxo Group 
Research, Ware, UK) and heparin sodium (Leo Pharma- 
ceutical Products, Weesp, Netherlands) to prevent clotting 
of the catheters. GR127935 was solubilized according to 
the instructions of the manufacturer by heating the disper- 
sion in distilled water to about 70°C and then allowing to 
cool down to room temperature. For in vitro experiments, 
all compounds ( ubstance P, prostaglandin F2~, sumatrip- 
tan and GMC2021) were dissolved in distilled water, while 
for in vivo experiments sumatriptan and GMC2021 were 
dissolved in physiological saline and all doses refer to the 
respective salts. 
3.  Resu l ts  
3.1. Systemic and carotid haemodynamics n anaesthetized 
pigs 
3.1.1. Systemic haemodynamics 
As shown in Table 1, in the saline-pre-treated animals 
GMC2021 elicited a slight decrease in heart rate (maxi- 
mum change: -5  ___ 1%), but arterial blood pressure de- 
creased more substantially (maximum decrease: 30 -t- 1%). 
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Fig. 3. Percent changes from baseline values by GMC2021 (30-1000 I-~g" kg - t ;  upper panels) in the total carotid blood flow and its arteriovenous 
anastomotic (AVA) and nutrient (capillary) fractions in anaesthetized pigs, pre-treated with either saline (n = 6) or GR127935 (0.5 mg,  kg- I ;  n = 6), 
Data recently obtained in similar experiments with sumatriptan (De Vries et al., 1996; lower panels; n = 4-5)  are presented for comparison, All values are 
presented as means ± S.E.M. a P < 0.05 vs. baseline; b p < 0.05 vs. corresponding change in the saline-pre-treated group. 
While pre-treatment of the animals with GR127935 (0.5 
mg. kg- 1 ) did not modify the effect of GMC2021 on heart 
rate, the effect on arterial blood pressure was significantly 
reduced (Table 1). 
3.1.2. Arterio-jugular venous oxygen saturation difference 
In the saline-pre-treated group, the arterio-jugular ve- 
nous oxygen saturation difference increased significantly 
after the highest dose (1000 Ixg'kg -~) of GMC2021. 
Table 2 
Absolute values (nun Hg • ml -  1 . min-  J ) of total carotid vascular esistance and its fractionation i to arteriovenous anastomotic and capillary (nutrient) 
parts at baseline and after cumulative doses of GMC2021 in animals pre-treated with either saline (n = 6) or GR127935 (0.5 mg,  kg - l ;  n = 6) 
Pretreatment GMC2021 (ixg. kg-1 ) 
Baseline 30 100 300 1000 
Total carotid resistance 
Saline 0.76+0.08 0.78+0.08(3-1-1) 0.82 + 0.09 (7 + 2) a 0.89 + 0.11 (15 + 5) a 
GR127935 0.98±0.19 0 .97±0.17(1+3)  1 .06+0.22(7+8)  1 .13±0,28(13+13)  
Arteriovenous anastomotic resistance 
Saline 0.95-1-0.10 1 .04+0.12(10±6)  1.18 + 0.14 (24 ± 6) a 1.45+0.22(51-1-15) a 
GR127935 1.70±0.55 1.71 -t-0,42 (9±6)  1.91 +0.54(16±7)  2 .00+0.56(22+ 11) 
0.99 + 0.14 (29 + 9) a 
1.15 ± 0.29 (19 + 16) 
2.19 ± 0.37 (125 _+ 26) a 
2.10±0.56 (35_+18) b 
Capillary (nutrient) resistance 
Saline 4.85-t-0.66 4.43-t -0.80(-12-1-6)  3 .35+0.54( -31+5)  a 3.03 + 0.55 ( -39  + 4) a 2.30 + 0.38 ( -52  + 5) a 
GR127935 3.46±0.40 2.99-1-0.37 (13+5)  3.24+0.55 ( -9±8)  b 3.75+0.94 (1+16)  b 3.53+0.85 ( -4±14)  b 
Percentage changes from baseline in each variable is given in parentheses. All values have been presented as means + S.E.M. ap < 0.05 vs. baseline; 
bp < 0,05 vs. corresponding dose in the saline-pre-treated group. 
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Pre-treatment with GR127935 antagonized the effect of 
GMC2021 (Table 1). 
3.1.3. Carotid haemodynamics 
As shown in Fig. 2 (absolute values) and Fig. 3 (upper 
panels; percentage change from baseline values), 
GMC2021 (30, 100, 300 and 1000 I~g kg -1, i.v.) elicited a 
dose-dependent decrease in both the total carotid and 
arteriovenous anastomotic blood flows, but the total capil- 
lary fraction was increased. The EDs0 of GMC2021 in 
decreasing arteriovenous anastomotic blood flow in the 6 
saline-pre-treated animals was found to be 467 _ 128 txg • 
kg -] (1.1 _ 0.3 Ixmol" kg -1) and with the highest dose 
(1000 txg • kg- J ) the decrease amounted to be 67 __+ 4%. In 
animals pre-treated with GR127935 (0.5 mg • kg-1), where 
the baseline values of arteriovenous anastomotic blood 
flow were less than in saline-pre-treated animals due to its 
partial agonist action (see De Vries et al., 1996), the 
GMC2021-induced ecreases in the total carotid blood 
flow and its arteriovenous anastomotic fraction were re- 
duced (the decrease in arteriovenous anastomotic blood 
flow by the highest dose was 29 + 8%) and the 
GMC2021-induced increase in the capillary blood flow 
was completely blocked (see Fig. 3; upper panels). In 
similar recent experiments, umatriptan decreased the total 
carotid and arteriovenous anastomotic blood flows, but the 
increase in the capillary blood flow was not statistically 
significant (De Vries et al., 1996). The EDs0 of sumatrip- 
tan in decreasing arteriovenous anastomotic blood flow 
was 63 _ 17 txg • kg -I (0.16 + 0.04 ixmol • kg - ] )  and the 
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Fig. 5. Effect of GMC2021 (30-1000 txg.kg - I )  on the distribution of 
carotid blood flow to skin and ears in anaesthetized pigs, pre-treated with 
either saline (n = 6) or GR127935 (0.5 mg.kg- t  ; n = 6). All values are 
presented as means_S.E.M,  a p < 0.05 vs. baseline; b p < 0.05 vs. 
corresponding change in the saline-pre-treated group. 
highest dose used (300 I~g • kg- 1 ) decreased arteriovenous 
anastomotic blood flow by 76 _ 4%. In animals pretreated 
with GR127935, the effects of sumatriptan were substan- 
tially reduced (0.25 mg. kg- ~ ) or completely blocked (0.5 
mg. kg - I )  (De Vries et al., 1996; Fig. 3, lower panels). 
The effects of GMC2021 on the total carotid vascular 
resistance and its fractionation i to arteriovenous and cap- 
illary parts are shown in Table 2. GMC2021 increased the 
total carotid and, particularly, the arteriovenous anasto- 
motic resistance, but decreased the capillary resistance. 
The effects of GMC2021 were much reduced (total carotid 
Do 
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Fig. 4. Effect of GMC2021 (30-1000 Ixg - kg -  t ) on the distribution of carotid blood flow to different cranial tissues in anaesthetized pigs, pre-treated with 
saline (n = 6). All values are presented as means + S.E.M. * P < 0.05 vs. baseline. 
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Fig. 6. Human isolated coronary artery. Contractile responses toGMC2021 
(n = 6) and sumatriptan (n = 6), both expressed as percentage of the 
response to 100 mM K +. 
and its arteriovenous anastomotic fraction) or completely 
blocked (capillary resistance) in animals pre-treated with 
GR127935. 
The distribution of carotid blood flow to the head 
tissues in the saline-pre-treated animals is depicted in Fig. 
4. GMC2021 did not significantly modify the fraction of 
carotid blood flow distributed to the brain, eyes, fat, 
muscles, bones or salivary glands, but skin and ear frac- 
tions increased significantly. The increase in skin and ears 
with the highest dose of GMC2021 were 97 + 49% and 
334 + 87%, respectively and these effects were completely 
antagonized in animals pre-treated with GR127935 (Fig. 
5). 
has often been reported with sumatriptan (Feniuk et al., 
1989; Den Boer et al., 1991a, 1992; De Vries et al., 1996); 
in similar experiments no changes in heart rate occurred 
after four consecutive bolus injections of saline (Den Boer 
et al., 1991a). The mechanism involved in the rather small 
decrease in heart rate by sumatriptan (or GMC2021) is not 
clear, but may be related to presynaptic inhibition of 
sympathetic neurons (Humphrey et al., 1988, 1990) or 
central 5-HT m receptor activation (Dreteler et al., 1989; 
Saxena and Villalrn, 1990). However, in any case, brady- 
cardia following the use of sumatriptan i patients eems 
to be of little clinical relevance (Saxena nd Tfelt-Hansen, 
1993). 
In contrast o sumatriptan (Den Boer et al., 1991a), 
GMC2021 produced a decrease in arterial blood pressure. 
This effect of GMC2021 was reduced in animals pre-treated 
with GR127935, implying a novel 5-HTlo receptor-media- 
ted mechanism, perhaps within the central nervous ystem. 
GMC2021 seems to enter the brain as suggested by hy- 
pothermia (+2°C) in the guinea-pig observed with this 
compound, but not with sumatriptan (K. Svensson, unpub- 
lished observations). Since the hypotensive ffect of 
GMC2021 was not completely blocked in GR127935-pre- 
treated animals, a part of the action may be due to an 
agonist action on central 5-HTIA receptors; GMC2021 has 
a substantial affinity for 5-HT,A receptors (pKi: 7.40; K. 
Svensson, unpublished observations). 
4.2. Carotid haemodynamic changes 
3.2. Human isolated coronary artery 
3.2.1. Effect of substance P and K + 
Coronary vessel segments relaxed to substance P (1 
nM) after precontraction with prostaglandin F2~ (1 txM) by 
63 _+ 18% of the contractile responses to prostaglandin 
F2~. K + (100 mM) caused a mean contractile response of 
33.7 _+ 5.6 mN. 
3.2.2. Effect of sumatriptan and GMC2021 
As shown in Fig. 6, the human isolated coronary artery 
contracted to sumatriptan (pD2:6.12 _+ 0.15; E,,ax: 31.3 _+ 
12.3% of contractions to 100 mM K +) more potently than 
to GMC2021 (pD2:5.45 -I- 0.20; Emax: 21.0 +_ 4.8% of 
contractions to 100 mM K+). 
4. Discussion 
4.1. Systemic haemodynamic changes 
GMC2021 produced small decreases in heart rate (5 _ 
1% after the highest dose of 1000 ~g.kg- ] ) ,  both in 
saline- and GR127935-pre-treated animals. While it is 
recognized that this small change may not be drug-related, 
it has to be pointed out that a similar bradycardic effect 
GMC2021 (30, 100, 300 and 1000 ~zg • kg -1) elicited a 
dose-dependent reduction in the total carotid blood flow, 
which was exclusively due to a decrease in its arteriove- 
nous anastomotic fraction; the arterio-jugular venous oxy- 
gen saturation difference, however, increased significantly 
only with the highest dose. The effects of GMC2021 were 
qualitatively similar to, but less than those observed with 
sumatriptan i  the same experimental model (Fig. 3; see 
also Den Boer et al., 1991a; De Vries et al., 1996). The 
EDs0 of GMC2021 and sumatriptan i  decreasing arteri- 
ovenous anastomotic blood flow were, respectively, 1.1 + 
0.3 txmol • kg -1 (present experiments) and 0.16___ 0.04 
Ixmol • kg- ~ (De Vries et al., 1996). However, in contrast 
to sumatriptan-induced r uctions in the total and arteri- 
ovenous anastomotic blood flows, which were completely 
abolished by 0.5 mg.kg -1 GR127935 (De Vries et al., 
1996), the effects of GMC2021 were only partially blocked 
(see Fig. 3). The partial blockade of the vasoconstrictor 
effect of GMC2021 cannot be explained by the decrease in 
the baseline value (see Table 2), due to the agonist action 
of GR127935 (Pauwels and Colpaert, 1995; Watson et al., 
1995; De Vries et al., 1996). While this decrease in the 
baseline will tend to exaggerate the effects of GMC2021 
expressed as percentage change from baseline, the effect 
expressed in absolute values (i.e. ml • min -1) may in fact 
appear masked. Moreover, in the face of a similar agonist 
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action, GR127935 (0.5 mg. kg- ~) did completely block 
the responses to sumatriptan, which was more potent han 
GMC2021. 
Taking into account that sumatriptan (Peroutka and 
McCarthy, 1989; Schoeffter and Hoyer, 1989; Beattie et 
al., 1994), GMC2021 (K. Svensson, unpublished observa- 
tions) as well as GR127935 (Clitherow et al., 1994; 
Skingle et al., 1993; Pauwels and Colpaert, 1995; Watson 
et al., 1995) have high affinities for 5-HT1D receptors, our 
results suggest hat the GMC2021-induced constriction of 
carotid arteriovenous anastomoses i  partly mediated by 
5-HT1D receptors, reinforcing the view that 5-HT~-like and 
5-HT1D receptors may be identical. Although none of these 
compounds distinguish between 5-HT~o ~ and 5-HT~D ~
subtypes, the presence of the 5-HT~D a mRNA, but not 
5-HT~D ~ receptor mRNA, in human and bovine cerebral 
arteries (Hamel et al., 1993) indicates that the 5-HT~D ~ 
receptor mediates contractile responses in cranial vessels. 
The lack of complete blockade of GMC2021-induced 
porcine carotid arteriovenous anastomotic contraction by 
GR127935 may imply that, apart from a 5-HT~D receptor, 
another eceptor is involved in this effect of GMC2021. 
Although the nature of this receptor is not known, it is 
interesting to recall that, unlike 5-HT or sumatriptan, the 
effects of ergotamine and dihydroergotamine on porcine 
arteriovenous anastomoses are also only partially blocked 
by the 5-HT~ and 5-HT 2 receptor antagonist, methiothepin 
(Saxena et al., 1986; Den Boer et al., 1991b). If, indeed, a 
novel receptor mediates the contraction of carotid arteri- 
ovenous anastomoses, it would obviously provide another 
avenue for drug development against migraine. 
As reported earlier from our laboratory with sumatrip- 
tan (Den Boer et al., 1991a; De Vries et al., 1996), 
GMC2021 conspicuously increased blood flows to the skin 
and ears. Although these increases were not observed in 
animals pre-treated with GR127935, it may be argued that 
the dilatation of the skin and ear arterioles is an indirect 
consequence of the closure of arteriovenous anastomoses 
by GMC2021. On the other hand, Schoeffter and Hoyer 
(1990) have reported 5-HT receptors similar to the 5-HTID 
receptor subtype mediate endothelium-dependent relax- 
ations of porcine isolated coronary artery. 
4.3. Human isolated coronary artery 
GMC2021 contracted the human isolated coronary artery 
with a pD 2 of 5.45 and Ema x of 21.0% of contractions to 
100 mM K ÷. This effect was lower than that of sumatfip- 
tan (pD2: 6.12; Emax: 31.3% of contractions to 100 mM 
K+). It is known that the effects of sumatriptan on the 
human isolated coronary artery are mediated by a 5-HT l- 
like receptor (Connor et al., 1989; Bax et al., 1993), which 
may resemble the 5-HT1D a receptor subtype (Kaumann et 
al., 1994). In view of the lower pD 2 on coronary vessels as 
well as lower pK i value at the 5-HT1DI3 receptor of 
GMC2021 than the corresponding values for sumatriptan, 
it would seem that a 5-HT~Da-like receptor is also involved 
in the coronary vascular effects of GMC2021. 
4.4. Clinical perspectives 
Over the years it has been shown that a number of 
drugs effective in aborting migraine headaches, including 
the ergot alkaloids, ergotamine and dihydroergotamine 
(Johnston and Saxena, 1978; Schamhardt et al., 1979; 
Spierings and Saxena, 1980; Den Boer et al., 1991b), 
sumatriptan (Den Boer et al., 1991a) as well as several 
second generation 5-HT1D receptor agonists undergoing 
clinical evaluation in migraine (e.g., zolmitriptan, BMS- 
180048 and MK-462; Boulanger et al., 1995; Martin and 
Dixon, 1995; Saxena et al., 1996), are able to constrict 
carotid arteriovenous anastomoses, which may open up 
during the headache phase of migraine (see Heyck, 1969; 
Saxena, 1990, 1995; Ferrari and Saxena, 1993). It has 
recently also been found that sumatriptan can constrict 
dilated arteriovenous anastomoses in the human forearm 
(Van Es et al., 1995). Since GMC2021 constricted carotid 
arteriovenous anastomoses, we believe that this drug should 
also be able to abort migraine headaches in patients. The 
drug was pharmacodynamically less potent han sumatrip- 
tan, both in the experimental model predictive of therapeu- 
tic efficacy in migraine and in the model indicative of 
potential coronary side effects; the efficacy of GMC2021 
and sumatriptan i decreasing porcine arteriovenous anas- 
tomotic blood flow were almost equal (67 _ 4 and 76 + 4% 
by 1000 and 300 ixg.kg -t ,  respectively). However, a 
potential disadvantage of GMC2021 may be its hypoten- 
sive action, if also observed uring clinical usage. 
Further pharmacokinetic evaluation, particularly con- 
cerning the duration of action and the extent of oral 
absorbtion, two of the short-comings of sumatriptan (see 
Ferrari and Saxena, 1993; Saxena nd Tfelt-Hansen, 1993), 
will dictate the future development of GMC2021. How- 
ever, on the basis of experience with other triflated ana- 
logues, for example tetralin-based dopamine and serotonin 
receptor ligands (Sonesson et al., 1993, 1995), it may be 
expected that GMC2021 should have a good oral bioavail- 
ability and duration of action. Indeed, this last possibility 
is suggested by our preliminary observations that a single 
i.v. dose of GMC2021 elicited a biphasic reduction in 
porcine carotid blood flow (initial effect for 5-10 min 
followed by a later effect between 60 and 120 min). 
In conclusion, the results of the present experiments 
show that GMC2021, a close analogue of sumatriptan, 
causes constriction of porcine carotid arteriovenous anasto- 
moses (suggestive of therapeutic activity in migraine) and 
the human isolated coronary artery (possibly indicative of 
coronary side-effects). The constriction of arteriovenous 
anastomoses seems to involve a 5-HT~D receptors, but 
possibly also a novel receptor which could provide a new 
avenue for developing antimigraine drugs. 
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